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1.1. Protein Disulfide Isomerase family: a member 
of the thioredoxin superfamily 
Thioredoxins (Trx) are small globular proteins that are found in all living 
cells from archeabacteria to humans [Holmgren, 1985]. The 3-D structures of 
Trx proteins are highly conserved and are characterized by a central core, 
consisting of five β-sheets surrounded by four α-helices and their active sites 
are characterized by the CXXC sequence, also known as the “Trx-motif” 
(Fig. 1) [Holmgren, 1995; Martin et al., 1995]. This structural configuration 
is known as thioredoxin fold and is present in different protein families, such 
as protein disulfide isomerases (PDIs), in DSB (disulphide bond formation) 
proteins, in glutaredoxin (Grx), in the glutathione reductase and glutathione 
peroxidase. The structural features that are conserved in Trx family members, 
such as the Trx-fold and the specific primary and secondary structures, lead 
to a different reactivity in catalyzing protein disulfide interchange reactions. 
It has been shown that both active site cysteine residues play an important 
role in the differentiation of the properties across the family and the relative 
stability (depending on cysteines nucleophilicity) of thiolates determines 
whether these enzymes catalyze oxidation, reduction or isomerization of thiol 
Introduction 
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residues in protein substrates [Cheng et al., 2011; Hatahet et al., 2009; 
Carvalho et al., 2009].  
 
Figure 1. The typical Trx-fold. 
 
PDI proteins with active Trx-domains are generally localized in the lumen of 
the endoplasmic reticulum (ER), where they mediate thiol-disulfide 
interchanges critical during post-translational protein folding [Galligan & 
Petersen, 2012]. 
The protein disulfide isomerase (PDI) family is composed of 21 known 
proteins in humans, that belong to the thioredoxin superfamily, classified by 
sequence and structural homology (Fig. 2). 
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Figure 2. PDI family members in humans. In blue: catalytic domains a and a’, in green and 
purple non-catalytic b and b’ domains. 
 
These enzymes catalyze the formation, reduction or isomerization of 
disulfide bonds of newly synthesized proteins in the lumen of the 
endoplasmic reticulum (ER). They are also part of a quality-control system, 
thanks to their molecular chaperone function. These proteins show a 
structural organization with multiple domains; each domain shows the typical 
Trx-fold and two or three of these domains contain the redox-active -CXXC- 
motif, while the others are considered Trx inactive domains [Turano et al., 
2002]. Because of these redox-inactive domains, PDIs have the ability to 
bind peptides or proteins and to exert a molecular chaperone function [Ferrari 
et al., 1999; Ellgaard et al., 2005]. The number, the arrangement of 
tioredoxin-like domains and the specific sequence of the catalytic -CXXC- 
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motif can be used to differentiate the members of this family. These 
differences determine their distinct role in the oxidative folding, but also 
contribute to their specific functions in other pathways. Furthermore, the 
differences in their redox active motifs can reflect separated roles in 
oxidation, reduction and isomerization (Fig. 3) [Kozlov et al., 2006]. 
 
Figure 3. PDIs disulphide bond exchange. Depending on the redox form, they can 
catalyse oxidation, reduction or isomerization. 
 
1.2. PDIA3 protein 
1.2.1. PDIA3 structure and functions  
PDIA3, also known as ERp57, ERp60, GRP58, and 1,25D3-MARRS; 
encoded by PDIA3, is a prominent member of the PDI family that has 
attracted significant attention by the research community. PDIA3 was first 
detected as a stress-responsive protein with upregulated expression following 
glucose depletion-induced cellular stress [Lee et al., 1981]. Trx-like domains 
of the PDI proteins are present as catalytically active domains (a or a′) or 
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inactive domains (b or b′). Each domain contains a Trx-like fold with 
alternating α-helices and β-strands [Ferrari et al., 1999; Kozlov et al., 2006; 
Silvennoinen et al., 2004]. PDIA3 is structurally similar to PDI, containing 
four TRX-like domains (a-b-b′-a′; Fig. 4), with matching redox active CGHC 
motifs and similar reduction potentials of the enzymes dual catalytic domains 
[Hatahet & Ruddock, 2009; Kozlov et al., 2006]. 
 
Figure 4. PDIA3 Protein modular structure. 
 
The catalytically inactive central domains, b and b′, have a vital role in the 
specific functionality of PDIA3 in protein binding and folding. The N-
terminal signal sequence directs initial ER localization while the C-terminus 
contains a QDEL ER retention/retrieval motif [Khanal & Nemere, 2007]. 
PDIA3 is classically considered an ER resident protein, but also contains a 
nuclear location sequence. Indeed, there are evidences that the stimulation 
with various macrophage differentiation-inducing agents and cellular 
stressors is able to induce PDIA3 transfer from cytoplasm to nucleus [Grillo 
et al., 2006; Grindel et al., 2011; Wu et al., 2010]. PDIA3 has also been 
detected on cell surface [Khanal & Nemere, 2007], as well as in mitochondria 
[He et al., 2014; Ozaki et al., 2008]. Regardless of the mechanism(s) 
underlying PDIA3's subcellular localization, it is clear that the enzyme's 
activity is not limited to those attributed to classical ER-resident proteins 
(Fig. 5). 
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Figure 5. Representative PDIA3 cellular localizations and functions. 
1.2.2. PDIA3 localization in the ER 
PDIA3 is mainly located in the ER, where it participates to the correct 
folding and to the quality control of neo-synthesized glycoproteins destined 
to be secreted or localized to the cell membrane. To do this, PDIA3 interacts 
with lectins calreticulin (CRT) or calnexin (CNX), which are responsible for 
recognizing and binding to monoglycosylated proteins [Oliver et al., 1997; 
Molinari et al., 1999; Oliver et al., 1999]. It has been reported that 
modifications of specific residues in the b’ domain of PDIA3 reduce or 
abolish its binding to calreticulin, indicating that this domain is responsible 
for this interaction [Russell et al., 2004]. PDIA3, in complex with CRT/CNX, 
performs disulfide shuffling, a process that requires the intermediate 
formation of a mixed disulfide between the glycoprotein and the proximal 
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cysteine of one of the two active sites of PDIA3. The shuffling is then 
completed by the intervention of the distal cysteine present in the same active 
site. A second important function of PDIA3 in the ER is the participation in 
the assembly of the major histocompatibility complex (MHC) class I 
[Lindquist e al., 1998]. An efficient antigen processing through the MHC I 
requires the formation of the peptide-loading complex (PLC). This complex 
consists of the transporter associated with antigen processing (TAP) as 
centerpiece, which recruits the major histocompatibility complex class I 
(MHC I) heavy-chain/β2-microglobulin dimer by the adapter protein tapasin 
(Tsn). The transient Tsn-MHC I interaction is stabilized by PDIA3, and the 
endoplasmic reticulum (ER) chaperone calreticulin (CRT), which recognizes 
the monoglucose unit of N-core glycosylated MHC I molecules. In the PLC, 
PDIA3 interacts with tapasin [Dick et al., 2002]; the structure of this complex 
has been resolved at 2.6 Å resolution [Dong et al., 2009]; this was the first 
time in which the whole 3D structure of PDIA3 was obtained. Both a and a' 
domains of PDIA3 are involved in the interaction with tapasin. The cysteine 
57 in the a domain of PDIA3 forms a disulfide bond with cysteine 95 of 
tapasin, while the a' domain-tapasin interaction is entirely non-covalent. The 
tapasin-PDIA3 complex is essential in the assembly and the stabilization of 
the PLC where PDIA3 shows a structural role rather than a catalytic one. In 
fact, the suppression of PDIA3 affects the stability of PLC and decreases 
both the expression of MHC I on the cell surface and the peptide loading 
within the PLC [Garbi et al., 2006]. PDIA3 also modulates the activity of the 
sarco/endoplasmic reticulum calcium ATPase (SERCA), a Ca2+-ATPase that 
transfers Ca2+ from the cytosol to the lumen of the ER, by regulating the 
redox state of the sulfhydryl groups in the intraluminal domain of SERCA 
[Li et al., 2004]. 
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1.2.3. PDIA3 localization in the cytosol 
PDIA3 has been reported in the cytosol thanks to its interaction with other 
proteins. In this localization, it associates with STAT3 [Sehgal, 2003]. 
STAT3 is a member of the STAT (Signal Transducer and Activator of 
Transcription) family. In response to cytokines and growth factors, these 
proteins are phosphorylated by receptor-associated kinases and then form 
homo- or hetero-dimers that translocate to the cell nucleus, where they act as 
transcription activators. STAT3 is activated through phosphorylation of 
tyrosine 705, in response to various cytokines and growth factors including 
interferons, epidermal growth factor and interleukin-6 (IL-6). The binding of 
IL-6 family cytokines to gp130 receptor triggers STAT3 phosphorylation by 
JAK2. Hyperactivation of STAT3 is frequently observed in a variety of 
human cancers, including head and neck cancer [Yu et al., 2004; Yu et al, 
2009; Song et al., 2000]. Continuous STAT3 activation allows the growth 
and survival of cancer cells through modulation of cell cycle regulators (e.g., 
cyclin D1/D2 and c-Myc), upregulation of anti-apoptotic proteins (e.g., Mcl-
1, Bcl-xl, and survivin), downregulation of the tumor suppressor p53, and 
induction of angiogenesis by vascular endothelial growth factor (VEGF); 
these mechanisms lead to tumor progression and resistance to anti-cancer 
drugs [Frank, 2013; Yu et al., 2004; Yu et al, 2009]. It has been reported that 
PDIA3 modulates STAT3 activity [Eufemi et al., 2004; Chichiarelli et al., 
2010], although there are controversial results [Coe et al., 2010].  For 
instance, PDIA3 has been reported to interact with STAT3 and enhance its 
activity in melanoma and hepatoma cells [Eufemi et al., 2004; Chichiarelli et 
al., 2010], whereas other research suggested that this PDIA3-STAT3 
complex negatively affects STAT3 DNA-binding activity [Coe et al., 2010]. 
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Hence, the role of PDIA3 in the STAT3 activity regulation is not completely 
defined yet. 
As a further proof of PDIA3 presence in the cytosol, it was found in 
association with mTOR [Ramírez-Rangel et al., 2011]. mTOR is a serine-
threonine protein kinase, found in two multiprotein complexes called 
mTORC1 and mTORC2, which regulate cell proliferation. PDIA3 
contributes to the assembly of mTORC1, activates the kinase activity of 
mTOR, and also participates in the mechanism by which mTORC1 detects its 
upstream signals, such as stimulation by insulin or nutrients. PDIA3 over-
expression induces cellular proliferation, while PDIA3 knockdown opposes 
the proliferation induced by insulin and nutrients. It is reasonable that part of 
this behavior is related to the mTOR-PDIA3 interaction, considering that 
mTOR is involved in the regulation of proliferation [Ramírez-Rangel et al., 
2011]. 
1.2.4. PDIA3 localization in the nucleus 
PDIA3 was found for the first time in the nuclei of 3T3 cells and rat 
spermatids [Ohtani et al., 1993] and of chicken hepatocytes, where PDIA3 
was found mainly in the internal nuclear matrix fraction [Altieri et al., 1993]. 
This observation was not easily accepted initially, because it was considered 
unlikely that a protein provided with an ER retention signal can escape from 
the endoplasmic reticulum. However, nowadays there is strong experimental 
evidence, provided by different laboratories with a variety of experimental 
techniques, that PDIA3 can be found in the nucleus. It has been shown that 
PDIA3 is present in the nuclei of HeLa cells and that it interacts directly with 
DNA [Coppari et al., 2002]. PDIA3 interacts preferentially with A/T rich 
regions, and in general with DNA regions typical of the MARs (nuclear 
matrix associated regions) [Coppari et al., 2002; Ferraro et al., 1999]. The 
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DNA fragments immunoprecipitated with an anti-PDIA3 antibody from 
HeLa and Raji cells were enriched in sequences contained either in introns or 
in 5’-flanking regions of known genes [Chichiarelli et al., 2007; Chichiarelli 
et al., 2010]. This can be compatible with a gene expression regulatory 
function. Furthermore, the consensus sequences for STAT3 were found to be 
associated both with this transcription factor and with PDIA3 [Chichiarelli et 
al., 2010]. Because of the relatively low affinity for DNA and its lack of 
stringent sequence specificity, PDIA3 cannot itself be considered as a 
transcription factor, but it might be considered an accessory protein for 
transcription regulation, possibly maintaining the transcription factors in their 
proper redox state. 
Moreover, PDIA3 shows in vitro DNA-binding properties that are strongly 
dependent on the redox state of the protein. The DNA binds to the a' domain 
[Grillo et al., 2002] and the binding requires the oxidized form of PDIA3 
[Ferraro et al., 1999; Grillo et al, 2007].  Evidences, from M14 melanoma 
cells and HepG2 hepatoma cells, demonstrated the association of STAT3 and 
PDIA3 also in the nucleus at the level of DNA interaction [Eufemi et al., 
2004; Chichiarelli et al., 2010]. The PDIA3 silencing in M14 cells causes a 
decrease in the expression of the STAT3-dependent gene CRP [Chichiarelli 
et al., 2010], suggesting the possibility of a positive involvement of PDIA3 in 
the signalling and/or DNA binding of STAT3.  
In NB4 leukemia cells, PDIA3 and NFkB translocate to the nucleus after 
treatment with calcitriol and phorbol ester [Wu et al., 2010], hypothesizing, 
again, a role of PDIA3 in the control of gene expression through regulation of 
the conformation of associated transcription factors. 
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Finally, PDIA3 displays in vitro and in vivo affinity for Ref-1, a protein 
involved in DNA repair as well as in the reduction and activation of 
transcription factors. These two proteins appear to cooperate in the activation 
of a variety of transcription factors, which need to be in their reduced form in 
order to bind DNA [Grillo et al.,2006]. 
1.2.5. PDIA3 localization on cell membrane  
The first time in which it was observed that PDIA3 can escape from the 
ER was when Hirano and colleagues noticed that the protein was being 
secreted from 3T3 cells [Hirano et al., 1995]. Afterwards several studies 
showed that PDIA3 could be found on the cell surface or in complexes with 
cell membrane proteins.  
PDIA3 has been found on the surface of the sperm head, where it is required 
for sperm-egg fusion [Ellerman et al., 2006]. Possibly the PDIA3 role is 
related to the thiol-disulfide exchange reactions necessary for the gamete 
fusion process. 
One of the functions of PDIA3 on the cell surface is the binding of the 
hydroxylated, hormonal form of vitamin D3, i.e., 1α,25-
dihydroxycholecalciferol (1α,25-(OH)2D3, calcitriol) [Nemere et al., 2004], 
followed by activation of non-genomic responses and the internalization and 
nuclear import of PDIA3 itself.  
It has been demonstrated that PDIA3 exists in caveolae, where it interacts 
with phospholipase A2 (PLA2) activating protein (PLAA) and caveolin-1 to 
initiate a rapid signaling in musculoskeletal cells via PLA2, phospholipase C 
(PLC), protein kinase C (PKC) and the ERK1/2 family of mitogen activated 
protein kinases (MAPK) [Boyan et al., 2012]. 
Moreover, it was recently reported that PDIA3 is associated and co-localizes 
with β-DG (one of the two subunit of the extracellular receptor dystroglycan, 
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DG) at the plasma membrane of 293-Ebna cells. It has been argued that 
PDIA3 may assist DG during its post-translational maturation or that it could 
modulate DG redox state [Sciandra et al., 2012]. 
PDIA3 is also present on the platelet surface and it has been showed that its 
inhibition blocks platelet activation [Holbrook et al., 2012; Wu et al., 2012]. 
PDIA3 is secreted by platelets and endothelial cells upon vascular injury and 
accumulates in the thrombus, where it regulates the activation and 
recruitment of other platelets [Holbrook et al., 2012]. 
Dihazi and colleagues [Dihazi et al., 2011] showed that PDIA3 was found to 
be secreted by renal cells in high amounts upon profibrotic cytokine 
treatment, and to interact with extracellular matrix (ECM) proteins, such as 
fibronectin and collagen. These data suggest that secreted PDIA3 could 
participate in ECM synthesis and stabilization, thus potentially leading to a 
progressive renal fibrosis. 
1.3. PDIA3 and diseases  
PDIA3 has been associated with several human diseases such as cancer, 
prion disorders, Alzheimer’s disease, Parkinson’s disease and hepatitis [Hetz 
et al., 2005; Martin et al., 1993; Muhlenkamp and Gill, 1998; Seliger et al., 
2001; Erickson et al., 2005; Tourkova et al., 2005]. PDIA3 expression is 
increased in transformed cells, and it is thought that its role in oncogenic 
transformation is directly due to its ability to control intracellular and 
extracellular redox activities [Hirano et al., 1995]. An increase in PDIA3 
expression has also been observed in the early stages of prion disease, 
suggesting that it may play a neuroprotective role in the cellular response to 
prion infection [Hetz et al., 2005]. Parkinson’s disease is characterized by the 
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progressive loss of dopaminergic neurons of the substantia nigra. It has been 
shown that the treatment of cell lines with 6-hydroxidopamine (6-OHDA, a 
Parkinson mimetic neurotoxin that selectively kills dopaminergic neurons) 
induces PDIA3 oxidation and PDIA3-DNA conjugates formation. It was 
suggested that PDIA3 plays an early adaptive response in toxin-mediated 
stress [Kim-Han et al., 2007]. 
1.3.1. PDIA3 and Alzheimer’s disease 
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder 
that is associated clinically with a progressive cognitive impairment 
[Cummings, 2004]. AD histology is characterized by the accumulation of 
amyloid β-peptide (Aβ) plaques and neurofibrillary tangles composed of 
hyperphosphorylated tau protein [Cummings et al., 2004].  The endoplasmic 
reticulum (ER) stress response is regarded as an important process in the 
aetiology of AD [see for review Hashimoto and Saido, 2018]. The 
accumulation of pathogenic misfolded proteins and the disruption of 
intracellular calcium signalling are considered to be fundamental mechanisms 
that underlie the induction of ER stress, leading to neuronal cell death. A 
number of reports have indicated that Aβ oligomers or fibrils trigger ER 
stress in in vitro experimental systems based on primary cultures of neuronal 
cells, cell lines and brain slices [Nishitsuji et al., 2009; Alberdi et al., 2013; 
Seyb et al., 2006]. Further investigations have proposed mechanisms 
establishing a connection between extracellular Aβ and intracellular ER. The 
most likely mediator between Aβ and ER stress is calcium, with the binding 
of Aβ to glutaminergic receptors likely to induce ER stress-dependent cell 
death by disrupting cytosolic calcium homeostasis [Costa et al., 2012]. In this 
scenario, a crucial role seems to be play by the mechanisms for promoting the 
clearance of neurotoxic and/or misfolded proteins, a strategy that may curtail 
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the onset and slow the progression of AD. Recent studies are exploring the 
involvement of the PDIA3 in the response to several types of stress in 
different neurodegenerative diseases, such as AD, Parkinson disease and 
Prion disease [Erickson et al., 2005; Kim-Han et al., 2007; Sepulveda et al., 
2016; Hettinghouse et al., 2018]. Available evidences indicate multiple 
distinct functional roles of PDIA3 under both physiological and disease 
states. In particular, under physiological conditions and during cellular stress, 
PDIA3 seems to play a role in cell protection against oxidative stress through 
its redox and chaperone activities, and it can prevent the development of 
diseases related to unfolded/misfolded proteins accumulation, such as Aβ [Ni 
et al., 2007; Ellerman et al., 2006; Plácido et al. 2014; Selinova et al., 2007; 
Erickson et al., 2005]. In line with the latter observation, it has been reported 
that diosgenin, a famous plant-derived steroidal saponin and structurally 
similar to the calcitriol, an endogen PDIA3 ligand [Nemere et al. 2012],  acts 
as an exogenous activator of PDIA3, improving the object recognition 
memory deficit and reduce amyloid plaques and neurofibrillary tangles in the 
cerebral cortex and hippocampus of 5XFAD mice, an engineered mouse 
model of AD harboring five familial AD mutations [Tohda et al., 2012]. 
Likewise, diosgenin derivative, caprospinol (diosgenin 3-caproate), reduced 
amyloid deposits and improved memory dysfunction in Aβ1-42-infused AD 
model rats [Lecanu et al., 2010]. Furthermore, it has been demonstrated that 
PDIA3 expression levels significantly increased after Aβ1-42 treatment in 
HMO6 cells, an immortalized human microglial cell line, and in microglial 
cells from 5XFAD mouse brains [Yoo et al., 2015]. Collectively these 
observations highlighted that PDIA3 may play a crucial role in microglia 
activation during AD and that it may be a molecular target for AD treatment. 
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Although these promising observations, the data are sparse and mostly the 
relationship between alterations in PDIA3 expression and the development of 
AD neuropathology is still unclear. 
1.3.2. PDIA3 and platelet aggregation 
Platelets play a central role in the hemostatic process, including 
recognizing the site of injury, recruiting additional platelets by intercellular 
signaling, adhering to each other, and interacting with the coagulation 
cascade to form a haemostatic plug. Inappropriate platelet activation, and 
subsequent thrombus formation, is important in the clinical complications of 
arterial atherosclerosis and thrombosis. Platelets are activated by a variety of 
agents which act to recruit additional platelets to the site of injury, leading to 
the consolidation of the aggregate. 
This activation process is initiated by the engagement of a range of specific 
cell surface receptors and associated to intracellular signaling pathways: 
✓ Exocytosis of granular products: ADP, serotonin, calcium and 
fibrinogen are important in the recruitment of platelets to the site of 
injury.  
✓ Expression of granular membrane proteins: Adhesive proteins (e.g., 
GPIb, P-selectin, CD63, and several integrins) have been shown to be 
present on the membranes of intracellular granules and are expressed 
on the surface of activated platelets. 
✓ Eicosanoid formation: The arachidonic acid cascade is initiated, 
leading to Thromboxane A2 (TXA2) synthesis. TXA2 is a platelet 
agonist that plays a pro-aggregatory role. 
✓ Surface expression of adhesive receptors: There is a conformational 
change in the αIIbβ3 integrin on the platelet surface from an inactive 
to an active configuration, exposing a fibrinogen and von Willebrand 
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Factor binding domain on the αIIbβ3 integrin that facilitates inter-
platelet binding [McNicol and Israels, Critical Review, 2003].  
PDIA3 is also present on the platelet surface and it is secreted by endothelial 
cells upon vascular injury and accumulates in the thrombus, where it 
regulates the activation and recruitment of other platelets [Holbrook et al., 
2012]. In fact, it has been demonstrated through proteomic approach that 
PDIA3 is upregulated and released after GPVI activation, a glycoprotein 
receptor for collagen [Holbrook et al., 2012; Zhou et al., 2014]. Anti-PDIA3 
antibody inhibits platelet aggregation, ATP secretion, calcium mobilization 
and activation of glycoprotein IIb/IIIa or fibrinogen receptor (αIIbβ3) in 
platelets stimulated with collagen-related peptide (CRP-XL), while platelet 
factor 4 (PF4) and P-selectin expression is minimally altered [Wang et al., 
2013; Holbrook et al., 2012]. Genetically engineered mice lacking platelet-
derived PDIA3 have prolonged tail bleeding times. PDIA3-null platelets 
reveal decreased platelet aggregation and decreased activation of αIIbβ3 [Wu 
et al., 2012]. β3 integrins pair with αIIb on the surface of platelets to create 
fibrinogen receptor αIIbβ3, the integrin activation is accompanied by several 
conformational changes that require a new pattern of disulfide bond 
formation [Zhou et al., 2014]. PDIA3 binding β3 integrin in thrombin-
activated platelets is probably involved in platelets aggregation, due to its 
redox activity; however, the underlying mechanism is not completely 
understood. [Schulman et al., 2016]. 
1.4. Polyphenols 
Flavonoids are a large class of polyphenolic compounds ubiquitous in 
plants and mostly present in fruits, vegetables and plant-based beverages 
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such as tea and wine [Perez-Jimenez et al., 2010]. Flavonoids are further sub-
classified in to flavones, flavonols, iosflavones, flavanones, flavanols and 
anthocyanidins (Fig. 6) [Manach et al., 2004; Bravo 1998]. 
 
 
Figure 6. Molecular structure of tested flavonoids. 
 
These physiologically active compounds have multiple well-known health 
beneficial effects. Many studies have suggested an association between 
consumption of flavonoids-rich food or beverages and the prevention of 
many degenerative diseases, including cancer, neurodegeneration and 
coronary heart disease and stroke [Woo et al., 2013; Hui et al., 2013; Hertog 
et al., 1993]. The protection offered by flavonoids is believed to be due to 
their antioxidant activity. The aromatic rings of the flavonoid molecule allow 
donation and acceptance of electrons from free radical species [Halliwell 
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2006]. In addition, many polyphenols regenerate the traditional antioxidant 
vitamins, vitamin C and vitamin E [Mandel et al., 2008] and act as metal 
chelators [Moridani et al., 2003].  It has been suggested that, in lower 
amounts, flavonoids as well as polyphenols may exert pharmacological 
activity within the cells, having the potential to modulate intracellular 
signaling pathways. Many polyphenols can induce antioxidant enzymes such 
as gluthathione peroxidase, catalase, superoxide dismutase, and inhibit the 
expression of enzymes such as xanthine oxidase, which is involved in the 
generation of free radicals [Alvarez-Suarez et al., 2011; Moskaug et al., 
2005].  However, for many of them the molecular and cellular bases of these 
activities are not known yet. 
Besides, data from literature indicate that several phytochemicals can be 
found in pomegranate fruits and can be a valuable aid in counteracting 
oxidative stress and preventing some major diseases. Pomegranate extracts 
have important biological properties, including anti-atherosclerotic, 
antioxidant, anti-inflammatory and antigenotoxics, properties that can help in 
preventing the development of chronic and debilitating diseases such as 
cardiovascular illnesses, type 2 diabetes and cancer [Jurenka 2008; Adams et 
al., 2006]. These activities have been attributed to the high content of 
phenolic compounds [Turrini et al., 2015; Medjakovic et al., 2013]. The 
nutraceutical properties of pomegranate are not limited to the edible part of 
the fruit; in fact, non-edible fractions of fruit and tree (e.g., peel, flower, …) 
contain even higher amounts of biologically active components. The peel of 
the pomegranate is rich in ellagitannins, such punicalagin, punicalin, gallagic 
acid, ellagic acid and glycosides (Fig. 7) [Akhtar et al., 2015; Masci et al., 
2016].  
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Figure 7. Chemical structure of punicalagin (A) and ellagic acid (B). 
 
Punicalagin, a unique pomegranate compound of high molecular weight 
soluble in water, is the predominant ellagitannin. Punicalagin features 
important biological activities, including anti-inflammatory, hepatoprotective 
and anti-genotoxic activities. However, there are currently few studies on 
punicalagin biological efficacy [Seeram et al., 2006]. 
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As above reported in Chapter 1, PDIA3 protein is a prominent member of 
the PDI family that has attracted a significant attention by the research 
community. It is also becoming increasingly evident that PDIA3 could be a 
pharmacological target in different pathological conditions, though the 
mechanisms in which it is involved are not completely understood. For this 
reason, my PhD project puts the spotlight on the PDIA3 involvement in 
disease processes, focusing on Alzheimer disease and platelet aggregation, 
and then characterizing its new features and roles in the development of the 
aforementioned diseases. At present, no selective compounds are known to 
modulate the PDIA3 biological functions. The discovery of specific PDIA3 
interactors could be used in repressing or stimulating PDIA3 in biological 
model, thus providing useful information on PDIA3 functions.   
2.1. Identification of specific natural PDIA3 
interactors able to bind and modulate its activity 
Polyphenol compounds display a wide range of biological effects, such as 
antioxidant, anti-inflammatory, antithrombotic, antiviral and antitumor 
activities [Vauzour et al., 2010]. They can act on different targets affecting 
regulation of a variety of pathways: cell signaling and cell cycle, free radical 
Chapter 2: Aim of the research 
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scavenging, inhibition of angiogenesis, initiation of DNA repair mechanisms, 
apoptotic induction and inhibition of metastasis [Williams et al., 2004; 
Mandel et al., 2011; George et al., 2016].  However, for many of them the 
molecular and cellular bases of these activities are not known. PDIA3 is a 
multifunctional protein disulfide isomerase with a wide range of functions 
and involved in many biological processes such as cellular response to stress 
as well as in cancer and neurodegeneration [Hettinghouse et al., 2018]. In this 
regard, it is interesting to undertake a screening study for assessing the 
interaction and impact on PDIA3 protein activity of several types of natural 
compounds. The identification of specific ligands that can modulate and/or 
inhibit PDIA3 interaction with specific partners may be useful to selectively 
control cellular processes and signaling pathways involving PDIA3 and 
might offer new therapeutic tools.  
This study, initially started in our lab by analyzing the major catechins 
present in the extracts of green tea [Trnkova et al., 2013], has been expanded 
to various classes of other natural compounds to assess their interaction and 
impact on PDIA3 protein activity. The binding of several polyphenols to 
PDIA3 were tested by fluorescence quenching assay. Their effects on the 
protein PDIA3 redox activity were also analyzed as well as their properties 
on a cellular model.  
2.2. Assessment of PDIA3 involvement in platelet 
aggregation 
In the last two decades, many research groups have focused on the 
development of new anti-aggregatory drugs in order to reduce the side effects 
or other draw-backs of older drugs. In fact, ASA (acetylsalicylic acid) is still 
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the drug of first choice for most relevant antiplatelet indications, but the 
major problem is 10-20% of clinical resistance. Furthermore, integrin αIIbβ3 
(fibrinogen receptor) is another interesting target and the antagonists of 
fibrinogen or von Willebrand Factor (e.g., abciximab, tirofiban, …) have a 
high antiplatelet potency but need to be given in intravenous way [McNicol 
and Israels, Critical Review, 2003]. Considering that the availability of oral 
drugs is limited, the identification of new drug targets is of clinical interest.  
Previous study demonstrated that danshensu has anti-thrombotic properties 
inhibiting the activation of αIIbβ3 and blocking the PDIA3/αIIbβ3 complex 
on the platelet surface [Cui et al., 2015]. Published data support the PDIA3 
role in platelet aggregation, though the intracellular mechanisms involved 
remain unclear. Several stimuli can trigger platelet aggregation, activating 
different intracellular pathways, as reported in Figure 8.   
 
 
Figure 8. Schematic representation of different intracellular pathways involved in platelet 
aggregation. 
It has been reported that PDIA3 can be released from platelets upon thrombin 
or collagen stimulation [Holbrook et al., 2010], demonstrating its possible 
involvement in their pathways. However, there are no evidences about the 
PDIA3 response via ADP or thromboxane A2 activation. 
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Hence, in my research, I used arachidonic acid and ADP as platelet 
activators, at different concentration, to investigate whether PDIA3 could be 
also involved in platelet aggregation through these ways.    
2.3. PDIA3 expression is altered in the limbic brain 
regions of triple-transgenic mouse model of 
Alzheimer's disease 
Evidences from the literature suggest that PDIA3 might have a role in AD 
pathogenesis [Erickson et al., 2005; Tohda et al., 2012], but its exact 
contribution is not clear. Therefore, we aimed to evaluate whether brain 
PDIA3 expression is altered in a triple transgenic model of AD (3×Tg-AD) in 
comparison with wild type littermates (Non-Tg). 3×Tg-AD mice, which 
harbor three mutant human genes [Oddo et al., 2003], mimic the critical 
aspects of AD-neuropathology observed in the human AD patients [Cassano 
et al., 2012; Romano et al., 2015; Scuderi et al., 2018]. Moreover, to 
investigate whether the temporal and regional patterns of such possible 
alterations might overlap with those of Aβ and tau pathology in this AD 
model, brain PDIA3 expression was analyzed at different ages [Oddo et al., 
2003]. As a consequence, by studying the temporal expression of PDIA3 in 
the wild-type littermates, our study has also allowed us to analyze the impact 
of aging on PDIA3 levels. Our analyses were conducted on PDIA3 protein 
levels in 3×Tg-AD and Non-Tg mice at two different stages (mild and 
severe) of AD-like pathology. In particular, 6- and 18-month-old mice were 
analyzed by Dot-blot analysis and double-immunohistochemistry, followed 
by the semi-quantitative analysis of the respective signals. Amygdala, 
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hippocampus (dorsal and ventral), and entorhinal cortex, all brain regions 
strongly affected by the AD-neuropathology, were analyzed in this study. 
Then, the triple-immunohistochemistry was performed in order to investigate 
the sub-cellular localization of PDIA3. Taking together, the expression and 
the localization may help us to speculate the role and the importance of 
PDIA3 in both healthy and Alzheimer’s condition. 
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3.1. Identification of specific natural PDIA3 
interactors able to bind and modulate its activity 
3.1.1. Chemicals 
Punicalagin, ellagic acid, phosphate buffered saline (PBS), tris(2-
carboxyethyl) phosphine (TCEP), dimethyl sulfoxide (DMSO), 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), dithiothreitol 
(DTT), oxidized glutathione (GSSG), eosin isothiocyanate, glutamine, 
sodium pyruvate, fetal bovine serum (FBS), penicillin and streptomycin and 
19 different flavonoids (quercetin, 3-O-methyl-quercetin, isoquercetin, 
quercitrin, rutin, morin, rhamnetin, isorhamnetin, fisetin, apigenin, apigenin-
7-glucoside, luteolin-7-glucoside, kaempferol, eupatorin, eupatorin-5-methyl-
ether, genistein, narigenin, cyanidin and 6,2’,4’-trimethoxyflavone were 
purchased from Sigma-Aldrich. EDTA (ethylenediaminetetraacetic acid) 0.5 
M solution pH 8.0 was from IBI Scientific and sodium 3´- [1- 
(phenylaminocarbonyl)- 3,4- tetrazolium]-bis (4-methoxy- 6-nitro) benzene 
sulfonic acid hydrate (XTT) from Biotium. SYPRO Orange was from 
Invitrogen. 
Chapter 3: Materials and methods 
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3.1.2. Protein expression and purification  
Human recombinant PDIA3 was cloned and expressed in E. coli strain 
BL21 using the expression vector pET21 (Novagen) as previously described 
[Coppari et al., 2002]. The coding sequence for the second redox-active 
domain (a’ domain, residues 377-505) was amplified by PCR as previously 
described and cloned in the expression vector pET29 (Novagen) [Grillo et al., 
2007]. Recombinant proteins were expressed in E. coli strain BL21 and 
purified by ammonium sulphate fractionation, ion exchange and heparin 
chromatography [Grillo et al., 2007; Grillo et al., 2006]. Protein purification 
was evaluated by SDS-PAGE and concentration was determined 
spectrophotometrically (PDIA3 Ɛ280 reduced form = 44,810 M-1cm-1, a’ 
domain Ɛ280 reduced form =14,400 M-1 cm-1). 
3.1.3. Fluorescence Quenching Measurements 
The PDIA3-ellagitannins/flavonoids interaction was evaluated by 
fluorimetric titration. Fluorescence spectra were recorded using a SPEX-
FluoroMax spectrofluorimeter (Horiba Scientific) from 300 to 500 nm with 
excitation at 290 nm using a 10 mm path length quartz fluorescence cuvette 
and under continuous stirring. The excitation and emission slits were both set 
to 5 nm and scan speed was 120 nm·min-1.  First, PDIA3 was reduced 
adding 2 mM TCEP to 50 μM PDIA3 stock solution. Then, aliquots of 
freshly reduced PDIA3 (0.5 μM or 0.1 μM final concentration) was diluted in 
PBS containing EDTA 0.2 mM and DTT 0.1 mM, and titrated in quartz 
cuvette by stepwise additions, at 5 min time intervals, of individual flavonoid 
solution (1 mM in PBS/ethanol 50:50 v/v freshly prepared from a 20 mM 
stock solution in DMSO) or of ellagitannins solution (punicalagin 0.2 mM in 
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PBS freshly prepared from a 20 mM stock solution in water, ellagic acid 0.2 
mM in PBS/ethanol 50:50 v/v freshly prepared from a 20 mM stock solution 
in DMSO). Most of tested flavonoids can absorb light at the excitation and 
emission wavelengths. To minimize the inner-filter effect, we limited the 
highest concentration reached in the titration test up to 10 µM. All 
experiments were carried out at 25°C. The blank spectra (polyphenol or 
flavonoids without protein) were recorded under the same experimental 
conditions and subtracted from the corresponding polyphenol-protein system 
to correct the fluorescence background. Fluorescence intensities recorded at 
338 nm were used for quenching analysis and obtained data, as the average of 
at least three independent titration experiments. 
3.1.4. Determination of Protein Disulfide Reductase 
Activity 
Disulfide reductase activity of PDIA3 was monitored by sensitive 
fluorescent assay using dieosin glutathione disulfide (DiE-GSSG) as 
fluorogenic probe. DiE-GSSG is synthesized by the reaction of eosin 
isothiocyanate with oxidized glutathione (GSSG) according to the method of 
Raturi and Mutus [Raturi and Mutus 2007] with some modifications 
[Trnkova et al., 2013]. DiE-GSSG purification was determined in HPLC and 
its concentration was calculated spectrophotometrically (Ɛ525=88,000 M-1cm-
1). Disulfide reductase activity was assayed in a reaction buffer containing 2 
mM EDTA, 150 nM DiE-GSSG, 5 µM DTT and 1µM or 50 nM PDIA3 in 
PBS. The effect flavonoid (20 µM) and ellagitannins (0.2, 0.5, 2, 5 and 20 μ) 
effects were evaluated after 2 minutes incubation before the analysis. GSSG 
reduction was monitored for 3 minutes at 545 nm with excitation at 520 nm, 
at 25°C under continuous stirring. Reductase activity was calculated as the 
initial velocity in fluorescence increase. A better investigation on PDIA3 
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reductase activity was performed by DiE-GSSG titration (31nM to 1000 nM) 
in reaction buffer added with 20 nM final concentration of PDIA3 and DTT 5 
μM. To assess the effect on the PDIA3 activity, before DiE-GSSG titration, 
PDIA3 20 nM was incubated with different concentrations of punicalagin 
(0.2, 0.5, 1, 2 and 5 μM) for 2 minutes. Values were fitted using the 
enzymatic kinetic equation on Graph Pad Prism 5.0 software (GraphPad 
Software, Inc.) to calculate Michaelis-Menten constant (Km) and maximum 
velocity (Vmax) for PDIA3 and their modifications after punicalagin 
treatment. Punicalagin inhibition constant (Ki) was determined using a 
Lineweaver-Burk plot or a Dixon plot analysis on Graph Pad Prism 5.0 
software. 
3.1.5. Isothermal titration calorimetry (ITC) 
The thermodynamic analysis of PDIA3-punicalagin interaction was 
obtained using the MicroCal ITC (Malvern Instruments Ltd.). PDIA3 was 
extensively dialyzed and punicalagin was dissolved in the same buffer. The 
sample cell (0.2 ml) was filled with PDIA3 (25 μM) and the syringe with 
punicalagin (250 μM solution). Ligand solution was then injected into the 
cell in 19 aliquots of 2 μL for 4 s (the first injection was 0.4 μL for 0.8 s) 
with delay intervals between injections of 180 s. Syringe stirring speed was 
set to 800 rpm. PDIA3-punicalagin interaction was analyzed in both non-
reducing and reducing condition. In the latter, 1 mM TCEP was added to 
protein and ligand solutions to ensure protein reduction. To correct the heat 
of dilution, titration of punicalagin into a buffer without PDIA3 was carried 
out. The thermodynamic data were processed with Origin 7.0 software 
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provided by MicroCal and used to calculate molar enthalpy, affinity constant 
and the stoichiometry of the reaction. 
3.1.6. Cell Culture 
Human bone marrow neuroblastoma cells (SH-SY5Y) were obtained from 
ATCC and PDIA3-silenced human bone marrow neuroblastoma cells 
(shPDIA3-SH-SY5Y) were obtained as follow. SH-SY5Y cells were cultured 
in 6-well plates and transfected with PDIA3 shRNA vector clone, obtained 
from the Mission shRNA library (Sigma), using Lipofectamine 2000 (Life 
Technologies) according to manufacturer’s instructions. Six hours after 
transfection, medium was replaced with fresh medium. After 48 hours 
1μg/mL puromycin was added to the cells to select stable transfected cell 
clones. Both neuroblastoma cell lines were grown to 60-70% confluence in 
Dulbecco’s Modified Eagle’s Medium Mixture F-12 Ham (DMEM F12) 
(Sigma-Aldrich) with 10% FBS, 1% w/v sodium pyruvate, 2mM glutamine, 
100 U/mL penicillin and 100 mg/mL streptomycin at 37°C in 5% CO2 (1 
μg/mL puromycin was added to shPDIA3-SH-SY5Y). 
3.1.7. Cell Viability 
To assess the cytotoxic effects of H2O2 and punicalagin, SH-SY5Y and 
shPDIA3-SH-SY5Y cells were seeded in 96-well plates and treated with 
different concentrations of H2O2 (0.05, 0.1, 0.2, 0.5, 1, 5 and 10 mM) or 
punicalagin (1, 2, 5, 10 and 20 μM) for 24 hours. Cell viability was measured 
using the XTT assay (Biotium) in accordance to the manufacturer’s 
instructions. Briefly, the culture medium was removed and 125 μL/well of 
XTT solution was added to 96-well plates. After 3-6 hours incubation, the 
orange formazan dye, resulting from the conversion of the XTT yellow 
tetrazolium salt by metabolically active cells, was measured at 450 nm and 
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690 nm using Appliskan plate reader (Thermo Scientific). To assess H2O2-
punicalagin co-treatment effects on cell viability, SH-SY5Y and shPDIA3-
SH-SY5Y cells were seeded in 96-well plates and pre-treated for 4 hours 
with 20 μM punicalagin followed by H2O2 treatment (0.1, 0.2 and 0.5 mM) 
for 24 hours. 
3.1.8. Cellular PDIA3 expression evaluated by Western 
Blotting 
Western blot analysis on cellular extracts was used to evaluate the effect 
of different H2O2 treatments on PDIA3 expression in SH-SY5Y cells and to 
test PDIA3 silencing in shPDIA3-SHSY5Y cells. Cells were seeded in 6-well 
plates, subjected to different treatments and then lysated in RIPA Buffer. 
Extracted proteins were quantified by Bradford assay, resolved on SDS-
PAGE in 10% TGX™ FastCast™ Acrylamide gels (BioRad), and then 
transferred to PVDF membranes (BioRad) using Trans-Blot® Turbo™ 
Transfer System (BioRad). Membranes were blocked with 1% w/v Bovine 
Serum Albumin (Sigma-Aldrich) in PBS. Membranes were incubated with 
anti-PDIA3 rabbit serum for 60 min, washed with TBST, and then incubated 
with peroxidase-conjugated anti-rabbit IgGs (Jackson ImmunoResearch) for 
an additional 60 min. After washing in TBST, the membranes were incubated 
with ECL substrates (Immunological Sciences) and the signal was detected 
by ChemiDoc™ Imaging Systems (BioRad). PDIA3 expression was 
analyzed using Image Lab™ Software (BioRad). Total proteins were used for 
normalization. 
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3.1.9. Statistical analysis 
Fluorescence quenching constant (KSV) values were given as means ± 
standard deviation and values of disulfide reductase activity were expressed 
in percentage of control sample ± relative standard deviation. All 
measurements were repeated at least three times. Dunnett’s test was used to 
compare the obtained reductase activity data with the activity of the untreated 
protein and a p-value of < 0.01 was considered as statistically significant. 
Statistical comparisons were performed using ONE-WAY or TWO-WAY 
Analysis of Variance (ANOVA) and post hoc Bonferroni’s test, with 
different H2O2 concentrations and punicalagin treatments as variables, using 
GraphPad Prism 5.0. The means of the data are presented with SEM. 
Statistical significance threshold was set to p < 0.05. 
3.2. Assessment of PDIA3 involvement in platelet 
aggregation 
3.2.1. Chemicals 
Lyophilized Arachidonic Acid (AA), ADP and prostaglandin E1 (PGE1) 
were purchased from Roche Diagnostics GmbH and solubilized in ultrapure 
water (vehicle).  EDTA (ethylenediaminetetraacetic acid) 0.5 M solution pH 
8.0 was purchased from IBI Scientific. 
3.2.2. Platelets isolations and activation  
Human blood was drawn from consenting, healthy, medication-free 
individuals in accordance with Czech Republic ethical procedures. Platelets 
were prepared on the day of experimentation. Blood was sampled in 
heparinized tube and centrifugated at 1500 rpm (200g) for 8-15 minutes in 
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centrifuge CS4. The platelet rich plasma (PRP) was transferred into a new 
plastic tube using a pipette with wide orifice and without disturbing the buffy 
coat layer, in order to avoid contamination. Saline solution was added at 1:1 
ratio (v/v), including PGE1 (1 μM final concentration) to prevent platelet 
activation. The tube was mixed very gently and then, centrifugated at 1000 
rpm (100g) for 15-20 min in centrifuge CS4 at room temperature (with no 
brake applied) to pellet contaminating red and white blood cells. The 
supernatant was transferred into new plastic tube using a pipette with wide 
orifice. Platelets were pelleted by centrifugation at 5400 rpm (800 g) for 15–
20 min at room temperature in centrifuge CS4. Platelet counts, by flow 
cytometry, were adjusted to the appropriate cell density by resuspension in 
saline (5*107 cell/ml). Platelet activation was induced by adding: AA (375, 
150 and 50 µM final concentration), ADP (10, 5 and 2,5 µM final 
concentration), ultrapure water as vehicle (control) and PGE1 as negative 
control (1 mM final concentration). After 15 minutes platelet aggregation at 
37°C, the activation was stopped by addition of EDTA-Na+ salt 1,45 mM 
final concentration. Platelets were centrifugated at 10000 rpm for 10 min. 
Stimulation of platelets using Arachidonic Acid, ADP was previous 
confirmed in Multiplate® Analyzer (Roche Diagnostics GmbH) with 
continuous stirring. Non-aggregatory conditions were detected by treating 
platelets with 1,45 mM EDTA-Na+ salt or with 1 mM PGE1. 
3.2.3. PDIA3 Immunoblotting 
Platelets were lysated in Lysis Buffer, vortexing and incubating on ice 15-
30 min. After spin, pellets were resuspended, and proteins were precipitated 
with addition of 10% v/v trichloro acetic acid and centrifugated at 14000 rpm 
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for 20 min then, pellets were washed with 70% cold acetone. Dried pellets 
were dissolved in Sample Buffer and incubated at 30°C for 2 hours. Samples 
were resolved on SDS-PAGE in 10% TGX™ FastCast™ Acrylamide gels 
(BioRad) and transferred to PVDF membranes (BioRad) using Trans-Blot® 
Turbo™ Transfer System (BioRad). Membranes were blocked with 1% w/v 
Bovine Serum Albumine (Sigma-Aldrich) in PBS. Membranes were 
incubated with anti-PDIA3 rabbit serum for 60 min, washed with TBST, and 
then incubated with peroxidase-conjugated anti-rabbit IgGs (Jackson 
ImmunoResearch) for an additional 60 min. After washing in TBST 
membranes were incubated with ECL substrates (Immunological Sciences) 
and the signal was detected by ChemiDoc™ Imaging Systems (BioRad). 
PDIA3 expression was analyzed using Image Lab™ Software (BioRad). 
Total proteins were used for normalization. 
3.2.4. PDIA3 immunoprecipitation from surrounding 
medium of aggregated platelets  
Platelets (5*107 cells/ml) were stimulated using Arachidonic Acid, ADP 
and stimulation was terminated as previously described. Cell-free 
supernatants containing platelet-released proteins were obtained by 
centrifugation at 14000 rpm for 20 min at room temperature. Collected 
supernatants were incubated with 8 µg of Anti-PDIA3 antibody (Ab) for 1-
1,2 hours at room temperature (RT) in rotation. Ab/protein complexes were 
added into 1 mg of Protein G-Dynabeads (Life Technologies), previously 
cleaned 2 times with Washing Buffer PH 7.4, and then incubated 2 hours at 
RT in rotation.  The tubes were placed on the magnet and the unbound part 
was recovered. The Dynabeads®-Ab-protein complexes were washed 3 times 
with Washing Buffer PH 7.4 and transferred in a cleaned tube during last 
wash, to avoid co-elution of proteins bound to the tube wall. The Ab-protein 
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complexes were eluted, on the magnet, adding 50 mM Glycine pH 2.8 and 
incubating for 10 minutes at RT. The Ab-protein complexes were recovered 
and added with sample buffer 4X and Tris 1M pH 7.4 to equilibrate the PH. 
Samples were heated for 10 min at 70°C. The recovered Ab-protein 
complexes were resolved on SDS-PAGE in 10% TGX™ FastCast™ 
Acrylamide gels (BioRad) and subjected to western blotting against PDIA3 
as above reported for total platelet extracted proteins. 
3.2.5. Statistical analysis 
Statistical comparisons were performed using ONE-WAY Analysis of 
Variance (ANOVA), with different concentrations treatment as variables, 
using GraphPad Prism 5.0. The means of the data are presented with SEM. 
Statistical significance threshold was set to p < 0.05. 
3.3. PDIA3 expression is altered in the limbic brain 
regions of triple-transgenic mouse model of 
Alzheimer's disease 
3.3.1. Animals  
6- and 18-month-old male 3×Tg-AD mice and their male wild-type 
littermates (Non-Tg) were used in this study. The 3×Tg-AD mice harboring 
PS1M146V, APPswe, and taup301L transgenes were genetically engineered 
by LaFerla and colleagues at the Department of Neurobiology and Behavior, 
University of California, Irvine. Colonies of 3×Tg-AD and Non-Tg mice 
were established at the vivarium of the Puglia and Basilicata Experimental 
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Zooprophylactic Institute (Foggia, Italy). The 3×Tg-AD mice background 
strain is C57BL6/129SvJ hybrid and genotypes were confirmed from tail 
biopsy. The housing conditions were controlled (temperature 22° C, light 
from 07:00–19:00, humidity 50%–60%), and fresh food and water were 
freely available. The study was performed in accordance with guidelines 
released by the Italian Ministry of Health (D.L. 26/2014) and the European 
Directive 2010/63/EU. All efforts were made to minimize the number of 
animals used in the study and their suffering. 
3.3.2. Protein isolation and Dot Blotting 
After cerebral areas collection, tissues were lysated in Lysis Buffer and 
extracted proteins were quantified by Bradford assay. Directly, 5 µg of 
proteins were spotted on nitrocellulose membranes using a dot blot apparatus. 
Membranes were blocked with 1% w/v Bovine Serum Albumine in 
phosphate-buffered saline (PBS). Membranes were incubated with anti-
PDIA3 rabbit (Millipore) for 60 min, washed with TBST and then incubated 
with anti-rabbit IgGs peroxidase-conjugated (Jackson ImmunoResearch), for 
an additional 60 min. After washing in TBST, membranes were developed by 
chemiluminescence with ECL substrates and the signal was detected by 
ChemiDoc™ Imaging Systems (BioRad). After stripping in glycine solution 
0.1 M pH 3.0 for 15 min and neutralization with PBS, membranes were 
blocked with 1% w/v I-block in TBS for colorimetric detection. Then, 
membranes were incubated with anti-β-actin mouse (Sigma) for 60 min, 
washed in 1% w/v I-block and incubated with anti-rabbit IgGs alkaline 
phosphatase-conjugated (Jackson ImmunoResearch), for an additional 60 
min. After washing in 1% w/v I-block in TBS solution, membranes were 
stained by colorimetric detection using alkaline phosphatase substrates 
(Quantace). The PDIA3 and β-actin protein expression was analyzed using 
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Image Lab™ Software (BioRad). The β-actin was used as house-keeping 
protein for normalization.  
3.3.3. Double-fluorescence immunohistochemistry 
Immunohistochemistry was performed using fluorescence-based revealing 
systems. For double fluorescence-based immunohistochemistry, 20-µm-thick 
brain coronal sections were obtained using a cryostat (Microm™ HM550, 
Thermo Fisher Scientific, MI, USA), and were mounted on positively 
charged microscope slides, which were stored at -20° C until further 
processed. The brain sections were incubated with 90% formic acid for 7 min 
followed by PBS washes. Then brain sections were blocked with a PBS 
solution containing 5% normal goat serum and 0.3% Triton X-100 followed 
by overnight incubation with purified anti-β-amyloid/APP 1-16 primary 
antibody (BioLegend®) and with PDIA3 rabbit polyclonal antiserum 
(Millipore) at 4°C. After removing primary antibodies, the slides were 
incubated with both secondary antibodies Alexa Fluor 594 goat anti-rabbit 
IgG and Alexa Fluor 488 goat anti-mouse IgG for 1.5 h at room temperature. 
After washing off excess secondary antibodies, the slides were incubated 
with Hoechst (Sigma). After washing excess Hoechst with PBS, the slides 
were mounted using an anti-fade medium (Fluoromount, Sigma-Aldrich). 
Furthermore, the specificity of the immunofluorescent staining for Aβ/APP 
and PDIA3 was confirmed on a separate set of slides by omitting the primary 
antibodies. 
3.3.4. Triple-fluorescence immunohistochemistry  
For triple fluorescence-based immunohistochemistry, each 20-µm-thick 
brain coronal section were mounted on a microscope slide and stored at ‒
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20°C. The slides were washed several times with PBS/Triton 0.1%. 
Subsequently, the slides were incubated for 20 minutes into a sodium citrate 
buffer pre-heated at 95°C. After the heat-induced antigen retrieval step, the 
slides were cooled at room temperature in a water bath and washed with 
PBS/Triton 0.1%. Before the incubation with primary antibodies, the brain 
sections were blocked with a solution containing 10% BSA and PBS/Triton 
0.3%. Thereafter, the slides were incubated for 16 h at 4°C with the primary 
antibodies: GFAP chicken polyclonal antibody (Abcam), NeuN mouse 
monoclonal antibody (Abcam) and PDIA3 rabbit polyclonal antiserum 
(Millipore). After washing off excess antibodies, sections were incubated 
with secondary antibodies: DyLight 350 goat anti-chicken, Alexa Fluor 488 
goat anti-mouse IgG and Alexa Fluor 594 goat anti-rabbit IgG for 1.5 h at 
room temperature. After washing off excess secondary antibodies, the slides 
were mounted with the anti-fade medium. Even in this case, the specificity of 
the immunofluorescent staining for GFAP, NeuN and PDIA3 was confirmed 
by the omission of primary antibodies in another set of brain sections. 
Fluorescence-based immunolabeled slides were observed using a Nikon 80i 
Eclipse microscope equipped with a Qicam 12-bit Fast 1394 digital camera, 
and NIS-elements BR software (Nikon, Tokyo, Japan).  
3.3.5. Statistical analysis 
The correlation analysis between Aβ and PDIA3 protein levels was 
performed on the respective optical densities measured on double 
immunofluorescent slices and expressed as percentage of those measured in 
6-month-old Non-Tg mice, by using the Pearson correlation test. The 
Aβ/APP and PDIA3 optical density values were analyzed by two-way 
ANOVA, with genotype (3×Tg-AD vs Non-Tg) and age (6 months of age vs 
18 months of age) as between-subject factors. Tukey’s honestly significant 
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difference test was used for multiple post hoc comparisons, when required. 
Statistical significance threshold was set at p < 0.05. 
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4.1. Identification of specific natural PDIA3 
interactors able to bind and modulate its activity 
4.1.1. Study of the natural compounds-PDIA3 interaction 
by fluorescence analysis 
We started a screening analysis to find molecules which specifically bind 
PDIA3. Such substances could be useful to modulate the biological functions 
of PDIA3. In this study, the interaction of different flavonoids with PDIA3 
and their effects on protein reductase activity were evaluated. Two 
polyphenols (i.e., punicalagin and ellagic acid) and a number of flavonoids 
(e.g., flavones, flavonols and several derivates), which differ in terms of 
skeleton structure as well as hydroxyl-, methoxyl- and other substituted 
groups, were analyzed (Fig. 6, 7).  
The interaction was investigated by quenching analysis of PDIA3 intrinsic 
fluorescence mainly due to the presence of three tryptophan residues. They 
differ from each other in solvent or quencher accessibility and can unequally 
contribute to the protein fluorescence. One tryptophan residue (W279) is 
buried in a hydrophobic pocket in the b´ domain, whereas the others (W56 
Chapter 4: Results  
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and W405) are present on the protein surface close to the thioredoxin-like 
active sites within a and a’ domains, respectively. Quenching analysis was 
performed on PDIA3, in the reduced form, by adding stepwise increasing 
concentration of each molecules and recording the protein fluorescence 
spectra. For some flavonoids the analysis was extended to isolate a’ domain 
(1 µM), always in the reduced form. Since all molecules can absorb light in 
the range of used excitation and emission wavelengths, in these experiments 
the highest final polyphenols concentration was kept stable to 10×10-6 M in 
order to limit their absorbance. Quenching effect on protein as well as Stern-
Volmer quenching constants (KSV) were calculated from the fluorescence 
intensities at 338 nm of protein alone (F0) and in the presence of increasing 
concentration of each ligand molecule (F) using the Stern-Volmer equation 
[Lakowicz 2006]:  
 
𝐹0
𝐹
= 1 + 𝐾𝑆𝑉[𝐿] 
 
where L is the ligand concentration. For each ligand molecule, the Stern-
Volmer quenching constant was obtained by linear regression of plots of 
𝐹0
𝐹⁄ versus [L].  
Representative fluorescence spectra of PDIA3 in the presence of increasing 
concentration of punicalagin are showed in Figure 9. 
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Figure 9. Protein fluorescence quenching analysis of PDIA3 in the presence of punicalagin. 
Protein fluorescence quenching analysis of PDIA3 in the presence of punicalagin (A) 
Fluorescence quenching spectra of reduced PDIA3 alone (solid line) and after stepwise 
addition of punicalagin (A) (dotted line) (pH 7.4, 25°C, and λex = 290 nm,).  (B) Stern-
Volmer plot of quenching data of reduced PDIA3 in the presence of increasing 
concentrations of punicalagin and ellagic acid. Data represent the mean of at least three 
independent experiments and error bars indicate SEM.  
 
A different degree of quenching was observed in presence of tested 
molecules. The decrease of fluorescence may indicate that the 
microenvironments of tryptophan residues in PDIA3 were altered due to the 
interaction with tested compounds. No evident spectral shift was noticed in 
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fluorescence spectra of PDIA3 after the additions of all tested molecules, 
suggesting that these substances do not induce any evident change in protein 
conformation. 
This interaction should involve regions of the protein near the two tryptophan 
residues, W56 and W405, more exposed to the solvent and close to the redox 
active sites. 
The apparent binding constants (Kb) was calculated using the equation 
described by Bi and colleagues [Bi et al., 2005]: 
 
log (
𝐹0 − 𝐹
𝐹
) = 𝑛 log𝐾𝑏 − 𝑛 log (
1
[𝐿𝑡] − 𝑛(𝐹0 − 𝐹)[𝐿𝑡]/𝐹0
) 
 
where F0 and F are the fluorescence intensities at 338 nm before and after the 
addition of the quencher, [L] and [Pt] are the ligand and the total protein 
concentrations, respectively. The number of binding sites (n) and the binding 
constant (Kb) were obtained by plotting log ((F0 – F)/F) versus log(1/([Lt]-n 
(F0 – F)[Pt]/F0)) using the reiterative calculation process described by Sun et 
al. [42], assuming a similar affinity for each binding site. The dissociation 
constant was calculated from the binding constant (Kd = 1/Kb). 
The estimated KSV, Kb and Kd values that characterize the interaction of 
PDIA3 with tested compounds are summarized in Table 1. 
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 KSV  
(M-1) 
Kq  
(M–1s–1) 
Kb  
(M-1) 
Kd  
(M) 
Flavone     
Trimethoxyflavon 22209 ± 484 2,22·1012 18123 55,2·10-6 
Eupatorin-5-methylether  90016 ±1875 9,00·1012 90440 11,1·10-6 
Eupatorin 89362 ±688 8,94·1012 96729 10,3·10-6 
Apigenin 54332 ±1185 5,43·1012 58739 17,0·10-6 
Apigenin-7-glucoside  43961 ±673 4,40·1012 47287 21,1·10-6 
Luteolin-7-glucoside  31601 ±484 3,16·1012 34557 28,9·10-6 
Flavanone     
Naringenin  16900 ±352 1,69·1012 17295 57,8·10-6 
Isoflavone     
Genistein  22953 ±435 2,30·1012 24409 41,0·10-6 
Flavonol     
Rhamnetin  28462 ±295 2,85·1012 30110 33,2·10-6 
Isorhamnetin  36109 ±1271 3,61·1012 32516 30,8·10-6 
3-O-methyl-quercetin  41110 ±794 4,11·1012 45719 21,9·10-6 
Fisetin 33164 ±542 3,32·1012 36862 27,1·10-6 
Kaempferol 28423 ±982 2,84·1012 26000 38,5·10-6 
Morin  24063 ±265 2,41·1012 25613 39,0·10-6 
Quercetin  46226 ±1406 4,62·1012 38987 25,6·10-6 
Quercitrin 29211 ±483 2,92·1012 32288 31,0·10-6 
Isoquercetin 25738 ±367 2,57·1012 29073 34,4·10-6 
Rutin  45197 ±465 4,52·1012 45527 22,0·10-6 
Anthocyanin 
  
  
Cyanidin 29761 ±635
 2,98·1012 29257 34,2·10-6 
Ellagitannin  
Punicalagin 
Ellagic Acid 
 
14115 ±4803 
74145 ± 3140  
 
14,9·1012 
7,4 ·1012 
120100 
40800 
8,3·10-6 
24,5·10-6 
 
Table 1. The estimated KSV, Kb and Kd values of the interaction of PDIA3 with tested 
compounds. Data were calculated from fluorescence quenching analysis using 0.5 or 0.1*10-
6 M PDIA3 in reduced conditions (pH 7.4, 25°C) and increasing concentration (0 to 10*10-6 
M) of different molecules. KSV are reported as mean and standard deviation of at least three 
independent experiments. The number of binding sites (n), the binding constant (Kb) and the 
dissociation constant (Kd) were estimated using the equation described by Bi et al. [Bi et al., 
2005] and the reiterative calculation process described by Sun et al. [Sun et al., 2010]. 
 
Although the protein can bind most of the tested substances, with an 
estimated dissociation constant within the 10-5 M range, some of them 
showed a better affinity. Molecules characterized by the highest binding 
constants are punicalagin and ellagic acid with a Kd around 1.0x10
-6 M. For 
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some flavonoids, the binding analysis was extended to the isolated a’ domain. 
Similar values for the binding constants were estimated, with some 
flavonoids showing a slightly better affinity for the whole protein respect to 
the isolated domain (data not shown). 
4.1.2. Effect of natural compounds on the PDIA3 redox 
activity 
To verify whether the interaction between flavonoids and PDIA3 may 
have an effect on protein functions, the disulfide reductase activity was tested 
using DiE-GSSG as fluoregenic substrate. For most of the molecules 
analyzed the effect on the redox activity of the protein was negligible. 
However, some molecules, in particular punicalagin but also the flavones 
eupatorin and eupatorin-5-methyl ether, showed an evident inhibitory effect. 
Others, such as morin, quercetin and cyanidin, had a less marked inhibition, 
approximately 20 (Fig. 10).  
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Figure 10. Comparison of polyphenols effect (at 20 μM) on PDIA3 reductase activity. Plots 
are displayed as mean and standard deviations of at least six independent measurements. 
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Data were analyzed by Dunnett’s test comparing PDIA3 activity in presence of each 
molecules with the activity of untreated protein. Significant differences are marked with 
asterisks (*p < 0.5, **p <0.01, *** p < 0.001).   
 
Considering the significant differences reported between punicalagin and all 
the molecules and its better affinity to PDIA3, we decided to better 
investigate this interaction. PDIA3 redox activity was tested in presence of 
different punicalagin concentrations and results were analyzed as logarithmic 
dose-response obtaining a half maximal inhibitory concentration (IC50) of 
about 1×10-6 M (Fig. 11).  
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      Figure 11. Logarithmic dose-response curve for punicalagin. Reductase activity of 
PDIA3 was recorded in the presence of increasing concentration of punicalagin and DiE-
GSSG as substrate. Activity was calculated as the fluorescence increase of DiE-GSSG 
after enzymatic reduction at a fixed time. Percentage of inhibition was referred to PDIA3 
reductase activity in absence of punicalagin. Data represent the mean of at least three 
independent measurements and error bars indicate SEM. [PDIA3] = 50×10-9 M, [DiE-
GSSG] = 200×10-9 M, [punicalagin] = 0.2×10-6 M to 20×10-6 M.   
Better characterization of punicalagin profile as PDIA3 inhibitor was 
performed changing both substrate and punicalagin concentrations. Data 
were analyzed using Lineweaver-Burk or Dixon plots (Fig. 12): it seems that 
punicalagin acts mainly as non-competitive inhibitor with a Ki of 0.39×10
-6 
M.  
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      Figure 12. Kinetic analysis of punicalagin. Lineweaver-Burk (A) and Dixon (B) plots 
were obtained analyzing the PDIA3 reductase activity in the presence of increasing 
concentration of substrate (DiE-GSSG) and punicalagin as inhibitor. PDIA3 activity was 
measured as the initial velocity recording the fluorescence increase that result from DiE-
GSSG reduction. Data represent the mean of at least three independent measurements and 
error bars indicate SEM. [PDIA3] = 20×10-9 M, [DiE-GSSG] = 62×10-9 M to 1000×10-9 
M, [punicalagin] = 0 to 5×10-6 M.  
On the basis of our data punicalagin-PDIA3 interaction should involve 
regions of the protein near the two tryptophan residues, W56 and W405, 
more exposed to the solvent and close to the active sites. Punicalagin does 
not seem to be affecting the binding of DiE-GSSG as substrate behaving 
mainly as non-competitive inhibitor. More probably punicalagin affects the 
conformational changes of cysteine residues at the active site that are 
required for the enzymatic activity. 
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4.1.3. Punicalagin effects on PDIA1  
PDIA3 and the homologous isoform PDIA1, although similar in overall 
domain structure and active-site motifs, carry out different functions that are 
the result of specialized substrate binding properties. These differences are 
mainly related to the C-terminal domains b’ and a’ that show the lowest 
homology between the two isoforms [Klappa et al., 1998; Pirneskoski et al., 
2001]. Then, we decided to compare the punicalagin effects on redox activity 
of PDIA1 and PDIA3 proteins. First, human recombinant PDIA1 was cloned 
and expressed in E. coli strain DH5α using the expression vector PET23-b 
(kindly donated by Professor Ruddock L. from Oulu University, Finland). 
Recombinant protein was expressed in E. coli strain BL21 and purified by 
nickel chromatography due to the presence of terminal His-Tag. Protein 
purification was evaluated by SDS-PAGE and concentration was determined 
spectrophotometrically (PDIA1 Ɛ280 reduced form = 45,567 M-1cm-1). The 
disulfide reductase activity of PDIA1 was monitored in the same 
experimental conditions, as reported above for PDIA3. Obtained data, 
reported in Figure 13, demonstrated that the PDIA3 redox activity respect to 
PDIA1, was already inhibited at low concentrations of punicalagin. Then, 
these preliminary data confirm that punicalagin is more specific for PDIA3, 
but other experiments must be performed to provide further evidence that 
confirm our hypothesis. 
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Figure 13. Comparison of punicalagin effects on PDIA3 and PDIA1. Reductase activity of 
PDIA3 and PDIA1 was recorded in the presence of DiE-GSSG, as substrate, and increasing 
concentration of punicalagin. Activity was calculated as the fluorescence increase of DiE-
GSSG after enzymatic reduction at a fixed time. Percentage of inhibition was referred to 
PDIA3 or PDIA1 reductase activity in absence of punicalagin. Data represent the mean of at 
least three independent measurements and error bars indicate SEM.  
4.1.4. Calorimetric analysis of Punicalagin-PDIA3 
interaction  
To further investigate the interaction of punicalagin with PDIA3, we 
decided to use calorimetric techniques to measure the thermodynamic 
parameters associated with the formation of the complex. The formation of 
the punicalagin-PDIA3 complex was analyzed by isothermal titration 
calorimetry (ITC). The measure of the absorbed or released heat, by protein 
titration with a ligand at constant temperature, yields the stoichiometry of the 
reaction, the binding enthalpy, and the affinity constant. ITC analysis was 
performed by adding punicalagin to PDIA3, in reducing condition and results 
are reported in Figure 14 and Table 2.  
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Figure 14. Binding of punicalagin to PDIA3 analyzed by ITC. Punicalagin-PDIA3 
interaction was analyzed by isothermal titration calorimetry. 2 µl aliquots of punicalagin 
(250×10-6 M) were stepwise added to sample cell (0.2 ml) containing PDIA3 solution 
(25×10-6 M) and heat variation was recorded. Data were processed with software provided 
by MicroCal. Upper panel: raw data of a representative experiment of punicalagin-PDIA3 
interaction. Lower panel: corresponding binding isotherm fitted according to the “one 
binding site” model. 
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Table 2. Thermodynamic data of punicalagin-PDIA3 interaction. Affinity constant (Kd), 
molar enthalpy (ΔH) and entropy (TΔS) of the reaction at 25°C were calculated processing 
data obtained from the isothermal titration. PDIA3 (25 x 10-6 M) was analysed in reduced 
and non-reduced conditions. 
 
Thermodynamic analysis confirms the binding affinity of punicalagin to 
PDIA3 with a Kd of 1.2×10
-6 M. ΔH always shows a negative value (-1.1 
Kcal/mol) while TΔS is positive (6.9 Kcal/mol) at 25 °C, thus indicating that 
both entropy and enthalpy contribute to reduce the system’s free energy. This 
result suggests non-covalent interactions formation at the binding interface, 
including van der Waals contacts, hydrogen bonds and other polar and apolar 
interactions.  However, the high positive TΔS value indicates that the solvent 
entropy gain, arising from the redistribution of water molecules, plays an 
important role.  
Punicalagin-PDIA3 interaction does not seem to be an enthalpy driven 
process but better fits with a lock-and-key model, which has been described 
as an entropy-dominated binding process. Since it is difficult to distinguish 
which factor, entropy or enthalpy, contributes more to ligand-protein 
interaction, a conformational selection binding model cannot be excluded 
[Du et al., 2016].   
 Kd (M) ΔH 
(cal/mol) 
TΔS 
(cal/mol) 
Reduced 
PDIA3 
1.2×10-6 -1.1×103 6.9×103 
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4.1.5. PDIA3 responses to H2O2 exposure in SH-SY5Y 
cells  
PDIA3 has been thought to be a participant in the mechanisms of cell 
protection against oxidative stress through its redox and chaperone activities. 
PDIA3 could efficiently help in reducing the intracellular level of oxidized 
proteins produced upon cell exposure to damaging agents and in preventing 
the accumulation of misfolded or self-aggregating proteins. We previously 
reported that the overexpression of PDIA3 in HeLa cells resulted in a marked 
protective effect against the oxidative insult of hydrogen peroxide [Grillo et 
al., 2006].  
To provide information on in vitro effects of punicalagin, we used, as cellular 
model, the neuroblastoma cell line SH-SY5Y. First, punicalagin effect on cell 
viability was assessed and no cytotoxic activity was observed using 
concentrations of punicalagin up to 20 μM (data not shown). Then, cell 
viability is progressively reduced after exposition to increasing 
concentrations of hydrogen peroxide (Fig. 15 A). Although cell response to 
oxidative stress can involve several activities, we focused on PDIA3 to test 
its behavior upon hydrogen peroxide exposition. Western blot analysis 
showed an increase of PDIA3 levels in stressed cells that becomes significant 
at the highest concentration of hydrogen peroxide tested (Fig. 15 B). Our 
results seem to confirm a PDIA3 involvement in cellular response to 
oxidative stress in this neuroblastoma cell line.  
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Figure 15. SH-SY5Y cell response to oxidative stress. SH-SY5Y cell were stressed by 
treatment with hydrogen peroxide at different concentration. (A) Cell viability was assessed 
by XTT assay. (B) PDIA3 expression levels were measured by western blot analysis on cell 
extracts. Inset shows a representative western blot image. Cell viability and PDIA3 
expression levels are expressed as percentage of measured data in stressed cells compared to 
those measured in unstressed cells (control) and referred to the same number of cells. Data 
represent the mean of at least three independent measurements and error bars indicate SEM. 
Data were subjected to statistical analysis and significant differences (p < 0.05) are marked 
with asterisks. 
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4.1.6. Punicalagin increases cell sensitivity to oxidative 
stress in SH-SY5Y respect to shPDIA3-SH-SY5Y cells 
Considering the above results, we tested whether punicalagin may affect 
the cell sensitivity to hydrogen peroxide treatment in the neuroblastoma cell 
model. Therefore, cells were preincubated with or without punicalagin and 
then subjected to oxidative stress by hydrogen peroxide treatment. Results 
show that the viability of cells exposed to different concentrations of 
hydrogen peroxide in the presence of punicalagin is always significantly 
lower compared to cells treated with hydrogen peroxide alone (Fig. 16 A). 
Supporting the idea that PDIA3 is one of the proteins involved in oxidative 
stress response, we can speculate that the observed punicalagin effect on 
neuroblastoma cell viability may be related to the above demonstrated ability 
of punicalagin to bind and modulate PDIA3 redox activity. Hence, we 
analyzed hydrogen peroxide cell sensitivity in PDIA3-silenced 
neuroblastoma cells under the same experimental conditions of wild-type 
cells, pre-treated with or without punicalagin. First, the silencing of PDIA3 
was assessed comparing PDIA3 expression level in wild type cells (wtSH-
SY5Y) and corresponding silenced cells (shPDIA3-SH-SY5Y) (Fig. 16 B). 
Figure 16 C shows that the presence or absence of punicalagin does not 
influence the cell viability in PDIA3-silenced cells exposed to hydrogen 
peroxide. A less evident effect of punicalagin can be observed only at the 
highest concentration of hydrogen peroxide and this can be explained since 
the silencing of PDIA3 in shPDIA3-SH-SY5Y cells was not fully achieved.  
Obtained data provide evidences that punicalagin increases the cell 
sensitivity to hydrogen peroxide in neuroblastoma cells but this effect is 
drastically reduced in PDIA3-silenced cells. This suggests that punicalagin 
effect can be, at least, partially due to its ability to influence PDIA3 redox 
64  Functional Characterization of Protein PDIA3 
 
 
activity, thus modulating the cellular sensitivity to hydrogen peroxide. We 
cannot exclude that other proteins, such as peroxidases and other redox 
enzymes, can be involved in cell response to oxidative stress and their 
activity can be modified by punicalagin. However, our preliminary results 
suggest that punicalagin acts as a PDIA3 ligand that can modulate its 
reductase activity also in a biological model. 
 
 
Figure 16. Punicalagin increases cell sensitivity to oxidative stress in SH-SY5Y respect to 
shPDIA3-SH-SY5Y cells. SH-SY5Y (A) and shPDIA3-SH-SY5Y (C) cells were stressed by 
treatment with hydrogen peroxide at different concentration in absence or presence of 
punicalagin 20×10-6 M. Cell viability was assessed by XTT assay. Cell viability is expressed 
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as percentage of measured data in stressed cells compared to that measured in unstressed 
cells (control) and referred to the same number of cells. Data were subjected to statistical 
analysis and significant differences (p < 0.05) are marked with asterisks. (B) PDIA3 
silencing was assessed comparing PDIA3 expression level in wtSH-SY5Y and 
corresponding silenced cells (shPDIA3-SH-SY5Y). PDIA3 expression levels were measured 
by western blot analysis on cell extracts and expressed as percentage of measured data in 
wild type cells. Inset shows a representative western blot image. 
 
4.2. Assessment of PDIA3 involvement in platelet 
aggregation 
4.2.1. PDIA3 protein levels after platelet stimulation 
To assess the PDIA3 protein basal level and the effects of vehicle 
administration on platelets, protein extracts from whole lysated platelets and 
treated-platelets with ultrapure water (control), were resolved by SDS-PAGE 
and then, subjected to western blot assay. It was also detected PDIA3 protein 
level under platelet aggregation inhibition following 1 mM PGE1 
stimulation. 
As reported in Figure 17, PDIA3 protein basal levels were not affected by 
vehicle (ultrapure water) treatment as well as to 1mM PGE1 stimulation. 
Indeed, no significant changes have been reported comparing whole lysated 
platelets to control or non-aggregated platelets (Fig. 17). 
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Figure 17. PDIA3 protein levels on platelet extracts. PDIA3 protein levels are expressed as 
percentage of measured data in treated-platelets with vehicle (control) and non-aggregated 
platelets compared to those measured in whole lysated platelets and referred to the same 
number of platelets (5*107/ml). Inset shows a representative western blot image. Data 
represent the mean of at least three independent measurements and error bars indicate SEM. 
 
Hence, PDIA3 protein levels were detected after platelet aggregation 
induction for 15 min adding AA (Arachidonic Acid) or ADP at different final 
concentrations. Western blot analysis shows that AA and ADP induced a 
PDIA3 decrease in a dose-dependent manner, that becomes significant at 375 
µM AA and 5 µM ADP, respectively (Fig. 18 A-B).    
  
 
Figure 18. PDIA3 protein levels on platelet extracts. PDIA3 protein levels are expressed as 
percentage of measured data in stimulated platelets with increasing concentration of A) AA 
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B) ADP compared to those measured in treated-platelets with vehicle (control) and referred 
to the same number of platelets (25* 106/ml). Inset shows a representative western blot 
image. Data represent the mean of at least three independent measurements and error bars 
indicate SEM. Data were subjected to statistical analysis and significant differences (p < 
0.05) are marked with asterisks. 
 
4.2.2. PDIA3 can be released under arachidonic acid and 
ADP treatment 
Previous studies have demonstrated that PDIA3 can be released into the 
surrounding media from activated platelets with thrombin or CRP-XL 
[Holbrook 20]. In order to investigate whether PDIA3 can be also released 
from platelets following stimulation with AA and ADP, platelets were 
activated and then removed from the cell suspension by centrifugation. 
Western blotting of platelet surrounding media shows that both AA and ADP 
can induce the release of PDIA3 from activated platelets (Fig. 19). It was also 
observed that both rested and PGE1-treated platelets released PDIA3, but 
since the experiments were performed starting from the same number of 
platelets (25*106/500µl), it can be speculated that the amount of secreted 
PDIA3 increased after AA and ADP stimulation. 
 
Figure 19. A representative western blot image of secreted PDIA3 from differently 
stimulated platelet. PDIA3 was immunoprecipitated from the surrounding medium from the 
same number of rested and treated platelets (25*106/500µl). 
 
68  Functional Characterization of Protein PDIA3 
 
 
4.3.  PDIA3 expression is altered in the limbic 
brain regions of triple-transgenic mouse model of 
Alzheimer's disease 
4.3.1. Alteration of PDIA3 expression in the limbic brain 
region  
PDIA3 protein levels were detected by dot blot assay in all considered 
cerebral areas. All the obtained data are reported in Figure 20.  
In order to evaluate the impact of aging on PDIA3 expression, different brain 
regions of the limbic system were evaluated in adult and aged Non-Tg mice. 
We observed a significantly decreased of PDIA3 levels in the amygdala (− 
38%, p < 0.05) and ventral hippocampus (− 40%, p < 0.01) of 18-month-old 
Non-Tg mice compared to 6-month-old Non-Tg mice; a trend toward a 
decrease was observed in the entorhinal cortex (− 14%, n.s.). 
To evaluate the effect of mild AD-pathology on the PDIA3 levels, 6-month-
old 3×Tg-AD mice were evaluated compared to aged-matched Non-Tg mice. 
Statistical analysis revealed that PDIA3 expression was significantly reduced 
in the amygdala (− 55%, p < 0.01), entorhinal cortex (− 41%, p < 0.001) and 
ventral hippocampus (− 46%, p < 0.01). 
Finally, to investigate whether the progression of AD-like pathology may be 
parallel with an altered expression of PDIA3 over time, we evaluated its 
levels at the mild and severe stage of the disease. Interestingly, 18-month-old 
3×Tg-AD mice showed a significant increase of PDIA3 levels in the 
amygdala (+ 130%, p < 0.01) and entorhinal cortex (+ 38%, p < 0.05), whilst 
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a trend toward an increase was observed in ventral hippocampus (+31%, n.s.) 
compared to 6-month-old 3×Tg-AD mice.  
 
 
Figure 20.  PDIA3 expression levels analyzed by Dot blot. 
PDIA3 protein levels were analyzed by Dot-blot in different brain regions of 6- and 18-
month-old Non-Tg and 3×Tg-AD mice.  Protein levels of all mice were normalized with 6-
month-old Non-Tg mice, that was used as control group. All data were analyzed by two-way 
anova; Tukey’s test was used as a post-hoc test to perform multiple comparisons (* p<0.05; 
** p<0.01; *** p<0.001). The main brain regions analyzed in this experiment are the 
following: A: amygdala; B: entorhinal cortex; C: ventral hippocampus. 
4.3.2. Aβ/APP-PDIA3 double-fluorescent 
immunostaining 
We performed a double-fluorescent immunostaining on different limbic 
areas of both 6- and 18-month-old mice, referred as the mild and severe 
pathology group, respectively. Two of three microphotographs of Aβ/APP-
PDIA3 double-fluorescent immunostaining (green and red stain, respectively) 
and scatterplot analysis of Aβ/APP vs PDIA3 protein levels are shown in 
Figures 21, 22.  
As previously reported [Cassano et al., 2012; Romano et al., 2014; Bellanti et 
al., 2017], in 3×Tg-AD mice we observed an age-dependent increase of the 
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Aβ/APP levels in all brain areas investigated in this study. Interestingly, 
scatterplot analysis indicated a direct correlation between PDIA3 expression 
and the build-up of Aβ pathology, but with different magnitude among the 
different brain regions considered. In particular, Pearson correlation test 
revealed a strong positive correlation in basolateral amygdala (r = 0.8132, p < 
0.001; Fig. 21), whilst a moderate but still positive correlation was observed 
in entorhinal cortex (r = 0.6606, p < 0.001; Fig. 22) and in ventral CA1 of 
hippocampus (r = 0.3378, p < 0.01; data not shown).  
Observing the patterns of PDIA3 subcellular expression, it seems that PDIA3 
has increasingly nuclear localization in aged mice of both transgenic and 
non-transgenic groups which may suggest its possible redistribution during 
AD development pathology and aging process. 
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Figure 21.  Aβ/APP-PDIA3 double-fluorescent immunostaining. A) Brain diagram which 
illustrate the site where the representative microphotographs were taken. B) Representative 
microphotographs of Aβ/APP-PDIA3 double-fluorescent immunostaining (green/red) 
performed on brain slices collected from 6- and 18-month-old Non-Tg and 3×Tg-AD mice; 
Hoechst 3342 (blue) was used as fluorescent counterstain. Original magnification: 10×; scale 
bar was set at 100 µm. C) Scatterplot analyses of Aβ/APP and PDIA3 levels in basolateral 
amygdala of 3×Tg-AD mice. Aβ/APP and PDIA3 levels were analyzed by Pearson’s and 
normalized with 6-month-old Non-Tg mice, that were used as control group. All data were 
analyzed by Two Way ANOVA; Tukey’s test was used as a post-hoc test to perform 
multiple comparisons. 
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Figure 22.  Aβ/APP-PDIA3 double-fluorescent immunostaining. A) Brain diagram which 
illustrate the site where the representative microphotographs were taken. B) Representative 
microphotographs of Aβ/APP-PDIA3 double-fluorescent immunostaining (green/red) 
performed on brain slices collected from 6- and 18-month-old Non-Tg and 3×Tg-AD mice; 
Hoechst 3342 (blue) was used as fluorescent counterstain. Original magnification: 10×; scale 
bar was set at 100 µm. C) Scatterplot analyses of Aβ/APP and PDIA3 levels in entorhinal 
cortex of 3×Tg-AD mice. Aβ/APP and PDIA3 levels were analyzed by Pearson’s and 
normalized with 6-month-old Non-Tg mice, that were used as control group. All data were 
analyzed by Two Way ANOVA; Tukey’s test was used as a post-hoc test to perform 
multiple comparisons.   
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4.3.3. GFAP/NeuN/PDIA3 triple-fluorescent 
immunostaining 
Previous studies have reported that PDIA3 transcript is abundantly 
expressed in all cerebral cell types [Landel et al., 2018], therefore we profiled 
the pattern of PDIA3 expression in both NeuN-positive differentiated 
neurons and GFAP-positive astrocytes in both 6- and 18-month-old 3×Tg-
AD mice, referred as the mild and severe AD-pathology group, respectively. 
In particular, a co-immunofluorescence analysis (GFAP-positive astrocytes: 
blue; NeuN-positive differentiated neurons: green; PDIA3-positive cells: red) 
was performed in different limbic areas from 3×Tg-AD and age-matched 
Non-Tg mice. We demonstrated that PDIA3 (red) co-localized with NeuN-
positive differentiated neurons (green) in brain regions of both genotypes at 
both time points considered as reported in two of three representative 
Figures, 23 and 24. Likewise, PDIA3 (red) co-localized with GFAP-positive 
astrocytes (blue), whose expression increased with an age-and genotype-
dependent fashion in the 3×Tg-AD mice as reported in two of four 
representative Figures 23 and 24. 
Interestingly, we also observed PDIA3-positive staining in several GFAP-
positive cells but NeuN-negative cells from all limbic areas (Figures 23 and 
24). Therefore, in order to determine to which cell population may belong 
these PDIA3-positive staining, the signal was detected either in the NeuN 
channel or in the GFAP channel. Based on the morphology and dimension of 
PDIA3- positive cells, we hypothesized that these cells may refer to either 
microglial cells or immature/suffering neurons. To this regard, it has been 
previously demonstrated that NeuN staining can be altered or lost in 
immature and/or suffering neurons [Lavezzi et al., 2013]. 
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Figure 23. GFAP/NeuN/PDIA3 triple-fluorescent immunostaining.  
A) Representative microphotographs of PDIA3/NeuN/GFAP triple-fluorescent 
immunostaining (red/green/blue) performed on brain slices collected from ventral 
hippocampus of 6- and 18-month-old Non-Tg and 3×Tg-AD mice. The yellow arrows 
indicate the PDIA3/GFAP co-localization. Original magnification: 20×; scale bar was set at 
100 µm. B) Representative microphotographs of PDIA3/GFAP co-localization in astrocytes 
of ventral CA1 from 18-month-old 3xTg-AD mice. 
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Figure 24. GFAP/NeuN/PDIA3 triple-fluorescent immunostaining.  
A) Representative microphotographs of PDIA3/NeuN/GFAP triple-fluorescent 
immunostaining (red/green/blue) performed on brain slices collected from basolateral 
amygdala of 6- and 18-month-old Non-Tg and 3×Tg-AD mice. The yellow arrows indicate 
the PDIA3/GFAP co-localization. Original magnification: 20×; scale bar was set at 100 µm. 
B) Representative microphotographs of PDIA3/GFAP co-localization in astrocytes of ventral 
CA1 from 18-month-old 3xTg-AD mice. 
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5.1. Identification of specific natural PDIA3 
interactors able to bind and modulate its activity 
The interaction of different natural compounds with PDIA3 and their 
effect on protein reductase activity were evaluated in a comparative analysis 
of protein intrinsic fluorescence quenching.  
Obtained data revealed a good interaction between PDIA3 and punicalagin, 
with a Kd in the micromolar range; moreover, its effect on protein 
fluorescence quenching is consistent with an interaction that involves one or 
both redox active sites. We also provide evidence that only punicalagin is 
able to strongly inhibit PDIA3 redox activity and kinetic studies suggest that 
this compound mainly acts as a non-competitive inhibitor with an estimated 
Ki of 0.39×10
-6 M. The binding of punicalagin to PDIA3 was further 
confirmed by calorimetric titration. Besides, comparative experiments 
conducted on wild type and PDIA3-silenced neuroblastoma cells suggest the 
potential of punicalagin to modulate PDIA3 reductase activity also in a 
biological model. In this regard, we can speculate that punicalagin could be 
used as a new PDIA3 inhibitor. 
Chapter 5: Discussions  
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Important biological actions have been ascribed to pomegranate, including 
cardiovascular protection [Aviram et al., 2002]. It was reported that 
pomegranate juice improves the lipid profiles in diabetic patients with 
hyperlipidaemia [Esmaillzadeh et al., 2004], while pomegranate flower 
extract diminishes cardiac fibrosis and improves cardiac lipid metabolism in 
diabetic rat models [Huang et al., 2005; Huang et al., 2005]. However, the 
contributions of punicalagin in pomegranate associated cardio-protective 
benefits remain largely unknown. Conversely, PDIA3 is significantly 
upregulated in both animal and human models of right and left heart failure 
and it has been proposed that PDIA3 may regulate SERCA 
(sarco/endoplasmic reticulum Ca2+-transport ATPase) activity and by 
extensive contribute to the calcium dysregulation that characterizes 
progressive heart failure [Vitello et al., 2012]. Then, considering our results, 
we can hypothesize that some of the cardio-protective effects of punicalagin 
could be related to its inhibitory activity towards PDIA3. 
Considering the different roles played by PDIA3 and its involvement in 
several types of diseases, finding strong and specific inhibitors of this protein 
could open a new field in the modulation of its activity and this study 
represents a starting point in this direction. 
5.2. Assessment of PDIA3 involvement in platelet 
aggregation 
Obtained data show that AA and ADP can modulate PDIA3 protein levels 
in a concentration dependent manner since there was a significant reduction 
only at 375 µM and 5 µM, respectively (Fig. 18 A-B). Besides, PDIA3 
protein levels did not change during platelet aggregation inhibition due to 1 
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mM PGE1 stimulation (Fig. 17) even if, also in this case, a not significant 
decrease has been reported.  Considering the ability of other PDIs and PDIA3 
to be secreted under different platelet aggregation stimuli [Holbrook et al., 
2010], the PDIA3 release was also assessed by immunoprecipitation from the 
surrounding medium of aggregated platelets with AA and ADP and reported 
data show that PDIA3 can be released also under these stimuli (Fig. 19). In 
conclusion, considering these observations and previous published data, it 
can be speculated that PDIA3 is involved in platelet aggregation not via 
selective pathways. Indeed, not only after thrombin and collagen platelet 
aggregation induction, but also after AA and ADP stimulation, the PDIA3 
decreased and was secreted. Then, it can be assumed that PDIA3 is involved 
in platelet aggregation not through specific and selective intracellular 
pathway, mediating by specific platelet inducers, but as a final platelet 
response independently from triggering stimulus. In addition to PDIA3, it has 
been reported that many thiol isomerases such as ERp5, ERp72 and PDI can 
be release from the platelet but the underlying mechanism is not clear 
[Holbrook et al., 2010]. It is likely that a storage pool of thiol isomerases 
exists within the platelet and they could be implicated in the regulation of 
platelet function. Since the release of PDIs might not be mediated by specific 
stimuli, though it could be the final consequence of platelet aggregation 
induction, these proteins can be considered new potential and intriguing drug 
targets. 
5.3. The study of PDIA3 profile in brain areas of 
3xTg Alzheimer murine model 
PDIA3 protein levels were detected by dot blot assay in different limbic 
areas. A significant decrease of PDIA3 levels in the amygdala, entorhinal 
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cortex and ventral hippocampus of 6-month-old 3×Tg-AD mice compared to 
aged-matched Non-Tg mice has been observed, demonstrating the effect of 
mild AD-pathology on PDIA3 (Fig. 20). The PDIA3 levels were also 
significantly reduced in the amygdala and ventral hippocampus of 18-month-
old Non-Tg mice compared to 6-month-old Non-Tg mice. These data 
confirm the impact of aging on PDIA3 expression in the considered brain 
regions (Fig. 20). The endoplasmic reticulum (ER) stress response is 
regarded as an important process in the aetiology of AD [see for review 
Hashimoto and Saido, 2018]. The accumulation of pathogenic misfolded 
proteins is considered to be a fundamental mechanism that underlies the 
induction of ER stress, leading to neuronal cell death [Costa et al., 2012]. In 
this scenario, a crucial role seems to be played by the mechanisms for 
promoting the clearance of neurotoxic and/or misfolded proteins, a strategy 
that may curtail the onset and slow the progression of AD. Abetas peptides 
are produced during the normal, post-translational processing of amyloid 
precursor protein (APP) [Lendon et al., 1997; Pirttila et al. 1994; Selkoe 
1999]. Under pathological conditions free abetas readily aggregate to form 
the insoluble deposits which are a major component of the plaque seen in 
Alzheimer disease [Pirttila et al. 1994]. Their low solubility suggests that 
plaque forms when the free, extracellular, abeta concentrations exceed their 
solubility constants [Lendon et al., 1997; Pirttila et al. 1994; Selkoe 1999]. A 
group of proteins which may serve as carriers to keep the abetas in solution 
are the ER chaperones. These have been shown to form complexes with 
several secretory and plasma membrane proteins [Holtzman 1998]. In this 
regards, Erickson and colleagues found that the bulk of the abetas were 
bound to PDIA3 and calreticulin into the cerebrospinal fluid (CSF) of 
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normals individuals, suggesting that these might be carrier proteins which 
prevent aggregation of the abetas and that the deposits are due to faulty ER 
post-translational processing of APP with the failure to form this complex 
[Erickson et al., 2005]. Our data showed that the intracellular PDIA3 protein 
amount reduced during the onset of the AD pathology (6-month-old 3×Tg-
AD mice) and in condition of aging (18-month-old Non-Tg). Therefore, this 
can be a consequence of protein secretion, in the view of previous published 
data, but also protein degradation. Indeed, we excluded the down-regulation 
of PDIA3 transcription since not relevant changes have been reported by RT-
PCR of the considered limbic areas (data not show). Furthermore, many 
authors have reported the PDIA3 ability to be released in different biological 
systems [Dihazi et al., 2013; Holbrook et al. 2010; Nardo et al., 2011], in line 
with the results from Erickson and colleagues, supporting our hypothesis 
about the possible PDIA3 secretion also in the neuronal system. It is well-
established the PDIA3 release from platelets under aggregation condition 
[Holbrook et al. 2010] or from endothelial cells under vascular injury 
[Holbrook et al., 2012]. Besides, it has been demonstrated that the secretion 
of PDIA3 is important for extracellular matrix accumulation and progression 
of renal fibrosis and is an early sign of disease onset [Dihazi et al., 2013]. 
Extracellular matrix proteins are translocated into the ER where folding takes 
place before secretion through the Golgi complex (Bedard et al., 2005; 
Hebert and Molinari, 2007). Hence, the levels of the chaperons are 
continuously adjusted to cope with stress conditions and to satisfy the needs 
of the cell (Dobson, 2003; Goldberg, 2003). Similarly, Almeida and 
colleagues have showed that the acute knockdown of PDIA3 reduced the 
progranulin (PGRN) secretion, whose mutations are implicated in the 
pathogenesis of familial frontotemporal lobar degeneration [Almeida et al., 
2011]. This finding was consistent with reports that PDIA3 is required for the 
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proper secretion of several other substrates [Ellgaard et al., 2005]. The role of 
secreted PDIA3 was also confirmed by Nardo and colleagues, since they 
identified PDIA3 and PDIA1 as possible biomarkers to monitor disease 
progression in blood samples from Amyotrophic Lateral Sclerosis cases 
[Nardo et al., 2011].  Thus, we can speculate that the intracellular PDIA3 
reduction in 6-month old 3xTg-AD mice could be due to its secretion to 
contrast the development of the disease. The same event could also take place 
in 18-month old Non-Tg mice in response of stressing condition following to 
neuronal aging. Due to its chaperone activity, the PDIA3 could be involved 
in detoxification and protection mechanisms required to help cells in 
reducing Aβ aggregates formation and their damaging activity in disease 
condition. In the same aforementioned manner for other pathological 
conditions, the PDIA3 secretion, in complex with Aβ or other protein, could 
prevent the development of the AD. Besides, to investigate whether the 
progression of AD-like pathology may be parallel with an altered expression 
of PDIA3 over time, we evaluated its levels at the mild and severe stage of 
the disease. Interestingly, 18-month-old 3×Tg-AD mice showed a significant 
increase of PDIA3 levels in the amygdala and entorhinal cortex, whilst a 
trend toward an increase was observed in ventral hippocampus compared to 
6-month-old 3×Tg-AD mice. These data demonstrate that PDIA3 is 
influenced by the mild and severe stage of the AD since PDIA3 protein levels 
change depending on the transgenic mice age. We hypothesize that, in 
presence of large amounts of Aβ aggregates due to the severe stage of the 
AD, PDIA3 can be involved in different pathways respect to its functions in 
the onset and mild stage of the AD. It has been reported that a depletion of 
PDIA3 reduced the phosphorylation activity of the mTOR-complex1 
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[Ramírez-Rangel et al., 2011]. This complex is a key component of a 
nutrient-sensitive signaling pathway and its activity is relevant for brain 
functions, regulating energy metabolism, synaptic plasticity as well as 
cognition. A persistent alteration of neuronal mTOR signaling has been 
linked to age-dependency cognitive decline and the pathogenesis of AD 
[Sarbassov et al., 2005; Di Domenico et al. 2017]. In effect, several studies 
demonstrated that Aβ can enhance mTOR signaling while rapamycin, a 
mTORC1 inhibitor, significantly reduced intracellular Aβ levels [Caccamo et 
al., 2010; Caccamo et al., 2011; Talboom JS et al., 2015]. Additionally, it has 
been reported that PDIA3 is necessary to mTORC1 assembly and affects its 
function in response to the oxidizing agent PAO. The authors suggested that, 
by interacting with mTORC1, PDIA3 could be part of the redox-sensing 
mechanism attributed to mTORC1 [Ramírez-Rangel et al., 2011]. Then, the 
stressing condition, due to the development of the pathology [Justice 2018; 
Sotiropoulos et al. 2011], may also alter the PDIA3 redox-sensor activity on 
mTORC1 contributing to its dysfunction. In this view, PDIA3 level could be 
relevant in mediating mTOR normal functionality, and either increased or 
decreased amounts will result in mTOR activity alteration cooperating in AD 
progression. Finally, the triple-fluorescent immunostaining, using GFAP as 
marker for astrocytes, NeuN as a marker for neurons and PDIA3, has been 
performed in limbic areas. Interestingly, the data obtained show the PDIA3-
positive staining in several GFAP-positive cells but NeuN-negative cells 
from all limbic areas (Fig. 23 and 24). We can suppose that those cells could 
be microglial cells and, indeed, they even appeared in 18-month 3xTg-AD 
mice. This could be due to the presence of neuroinflammation associated to 
Alzheimer disease. In fact, Aβ secretion is also related to microglia activation 
that could lead to a chronic inflammation typical of AD [Morales et al., 2014; 
Yoo et al., 2015]. Moreover, it has been observed that PDIA3 levels resulted 
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over-expressed in microglial cells stimulated by Aβ, probably to help the 
folding of newly synthesized glycoproteins in the ER [Yoo et al., 2015]. 
PDIA3 could perform a different role in microglial cells respect to neuronal 
cells. Thus, we can speculate that PDIA3 profile in microglial cells and 
neurons was completely different; in fact, while at least during the first 
period of AD the neuronal PDIA3 decreases to contrast the Aβ effects, in 
microglial cells it may enhance in response of increasing neuroinflammation. 
More deepen studies need to be performed to prove our hypothesis about the 
involvement of PDIA3 in Alzheimer disease. However, these preliminary 
data can be certainly considered a starting point in understanding such a 
mechanism. 
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The goal of my PhD project was to provide new information on the 
PDIA3 protein, a prominent member of the PDIs family, that could be a 
pharmacological target in different pathological conditions. 
I focused on the PDIA3 involvement in Alzheimer disease and platelet 
aggregation since limited information are provided by the literature for both 
conditions. Indeed, the data obtained from my research better clarify some 
aspect of PDIA3 functions in the two aforementioned situations. 
It has been shown that PDIA3 can be also released under AA and ADP 
platelet aggregation, and not only after thrombin and collagen stimulation. 
Therefore, the outcomes prove that PDIA3 is involved in platelet aggregation 
not via selective intracellular pathways, mediating by specific platelet 
inducers, but as a final platelet response independently from triggering 
stimulus. This aspect could make the PDIA3 a new potential and intriguing 
drug target in platelet aggregation pathologies.  
Conversely, the data from the Alzheimer’s research project clearly 
demonstrate that PDIA3 has dual profile, maybe performing different roles in 
the mild and severe stage of the AD. Indeed, in the mild stage of the disease, 
the reduction of PDIA3 protein levels could be associated to a protective 
cellular mechanism. At the opposite site, in the severe stage of the disease the 
re-increasing of the PDIA3 protein levels could be related to harmful effects, 
Chapter 6: Conclusions 
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modulating pro-aggressive mechanisms. Hence, in the light of what just said, 
the PDIA3 functions can be differently modulated in Alzheimer’s disease. In 
the mild stage of the AD the use of positive-PDIA3 interactors such as 
diosgenin could have beneficial properties in delaying the pathology while 
PDIA3 inhibitors could be used in repressing its harmful activity in the 
severe stage. At present, no specific PDIA3 interactors are available to 
negatively modulate its activity; for this reason, I focused part of my research 
in discovering possible PDIA3 inhibitors. Our data demonstrate that 
punicalagin is a new PDIA3 inhibitor with a Kd in the micromolar range and 
the ability to act as a non-competitive inhibitor with an estimated Ki of 
0.39×10-6 M. In this regard, punicalagin can be used to modulate PDIA3 
activity, on the one hand providing useful information about PDIA3 
functions in pathological conditions, and on the other hand using the 
punicalagin beneficial properties. 
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